Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and

Susanne Röger1, Raphaela Schneider2, Boris Rudic2

  • 1I. Medical Department, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim D-68167, Germany susanroeger@hotmail.com.

Insights

Cardiac contractility modulation (CCM) therapy is now feasible for heart failure patients with atrial fibrillation (AF). By upgrading devices to cardiac resynchronization therapy (CRT), CCM signals can be delivered, improving patient condition.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Treatment

Background:

  • Cardiac contractility modulation (CCM) is an electrical therapy for heart failure (HF) with reduced ejection fraction.
  • Current CCM algorithms require sensing natural p waves for signal delivery, inhibiting therapy in patients with atrial fibrillation (AF).

Purpose of the Study:

  • To demonstrate the feasibility of CCM therapy in patients with permanent AF.
  • To circumvent the need for natural p wave sensing in CCM therapy.

Main Methods:

  • Five patients with permanent AF received upgrades to cardiac resynchronization therapy (CRT) with low atrial sensitivity.
  • Atrial stimulation was used to mimic p waves, enabling CCM signal delivery.
  • Device performance and patient outcomes were monitored.

Main Results:

  • Successful CCM signal delivery was achieved in all patients by utilizing atrial pacing as a substitute for natural p waves.
  • Patients experienced significant clinical improvement, including reduced NYHA class, increased left ventricular ejection fraction, and improved quality of life.
  • High cardiac resynchronization therapy (CRT) and CCM stimulation rates were maintained throughout the follow-up period.

Conclusions:

  • CCM therapy is feasible in heart failure patients with permanent AF through sequential atrial-ventricular pacing.
  • This experimental approach offers a potential treatment option for select patients.
  • Development of a new CCM algorithm that does not require an atrial electrode is recommended.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K